Entities / Company
Pfizer.
American multinational pharmaceutical and biotechnology corporation
- Reports this week
- 18
- Active events
- 11
- Connections
- 766
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Pfizer and AT&T are discussed as blue-chip stocks as of June 30, 2026.Well supported4 reports1 development inside
-
Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.Some support1 report
-
AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Some support1 report
-
Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.Some support2 reports
-
Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.Some support1 report
-
Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.Some support1 report
-
Novartis and Pfizer provided talent to MindWalk Holdings Corp., while Shuji Sato and Joanne Lim joined the company.Some support1 report
-
Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.Some support1 report
-
India sought vaccines from Pfizer and Moderna during COVID-19, while Piyush Goyal emphasized the need for self-reliance.Some support2 reports
-
The article details multiple concurrent political and corporate investigations, including the EC's campaign against Rosatom in Hungary and an EPPO probe into Pfizer's Covid-19 procurement deal.Some support1 report
-
Kraft Heinz, Pfizer, and United Parcel Service are all facing financial challenges.Some support2 reports
Earlier this month
-
Verizon's Frontier deal increased debt, while Kraft Heinz and Pfizer stock traded on Nasdaq.Some support1 report
-
A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.Some support4 reports1 development inside
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
Moderna and Pfizer are developing defenses against Lyme disease, while Tarsus offers a pill for tick threats, amid surveillance discussions.Some support2 reports
-
AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.Some support1 report
-
Pfizer's performance is being analyzed in comparison to the broader market.Some support2 reports
-
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Well supported11 reports5 developments inside
-
Both Moderna and Pfizer utilize mRNA technology for gene therapy.Some support1 report
-
Prashanth was accused of using Pfizer labels to create fake products.Some support1 report
-
Whitney's grandfather purchased shares of Pfizer, and the company subsequently sent money to Florida.Some support1 report
-
Cross River State is partnering with Gavi and Pfizer for vaccine delivery and seeking cost reductions from Zipline.Some support1 report
-
FDA and Pfizer are seeking regulatory approval for their products.Some support3 reports
-
Getty Images provided the image source for an article involving Pfizer.Some support1 report
-
Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Some support2 reports
-
MarketBeat's screener has identified a list of dividend stocks.Well supported16 reports1 development inside
-
Pfizer and other companies are facing administration policy guidance regarding higher drug prices abroad in exchange for revenue sharing with HHS.Some support2 reports
-
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Well supported10 reports7 developments inside
-
Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.Well supported131 reports40 developments inside
-
FDA granted approval for Pfizer's updated vaccine on September 2, 2025.Well supported4 reports
-
GSK built a joint venture with Pfizer and subsequently distributed a stake in that venture to shareholders.Some support1 report
-
IMA Group operates a production site and manufacturing plant in Tonawanda, New York, providing specialized equipment to major customers like Pfizer and Moderna.Some support1 report
-
Former Pfizer HQ in Manhattan is discussed alongside Los Angeles as examples of major urban centers facing development challenges and structural issues.Some support1 report
-
Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.Some support2 reports1 development inside
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Some support1 report
-
Pfizer, AT&T, and Verizon are companies that trade on the New York Stock Exchange.Some support3 reports
-
Pfizer and Eli Lilly are being discussed as potential dividend investment targets.Well supported3 reports
-
Pfizer and Seagen are growing their older-adult vaccine market share by expanding the Prevnar 20 vaccination program and rebuilding their commercial model around acquired products.Some support1 report
-
Pfizer has refused to cooperate with local investigators regarding an incident in Karnataka.Some support2 reports
-
Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.Some support2 reports
-
MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.Some support1 report
-
The FDA suspended Pfizer's C&F Depot license.Some support2 reports
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
-
The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.Some support2 reports
One to three months ago
-
Trump promised drug discounts for low-income Americans and discussed Pfizer deals at a Dallas convention.Some support4 reports
-
Pfizer CEO Ugur Sahin sold shares of the firm's stock.Some support3 reports
-
Vaxcyte is targeting the market dominated by Pfizer, and a key individual involved in the story previously worked at Pfizer.Some support1 report
-
The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.Well supported6 reports1 development inside
-
Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.Some support3 reports4 developments inside
-
Pfizer and Boeing were tokenized for use in a crypto launchpad.Some support1 report
-
Pfizer conducted initial clinical trials under government review.Some support1 report1 development inside
-
DHS is piloting the 340B program, which affects products manufactured by Pfizer.Some support2 reports
-
Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.Some support2 reports
-
Rand Paul released Fauci's diary ahead of a hearing, while Israel provided Pfizer vaccine data to shape US booster policy.Some support4 reports
-
Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.Some support1 report
-
Pfizer is jointly marketing the drug Eliquis.Some support2 reports
-
Roivant Sciences licensed a drug from Pfizer for regulatory approval.Some support2 reports
-
Study results regarding a drug collaboration between Pfizer and Arvinas narrowed the focus to a specific subset of patients.Well supported4 reports
-
Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Pfizer
Events traced to Pfizer, step by step, newest first- Moderna's cancer vaccine leadership may challenge Pfizer's market positionModerna's success in cancer vaccines increases competitive pressure on Pfizer.Possible
- Moderna's cancer vaccine progress could challenge Pfizer's market positionModerna's advanced cancer vaccine and index inclusion may increase competitive pressure on PfizerPossible
- Increased focus on rivals may intensify competitive pressure on PfizerIncreased focus on AbbVie and Eli Lilly may intensify competitive pressure on PfizerPossible
- J&J's strong drug sales could increase competitive pressure on PfizerJ&J's strong drug sales may increase competitive pressure on Pfizer.Possible
- Shkreli's public stock campaigns may increase risk for PfizerShkreli's stock trading may increase risk for PfizerPossible
- BioNTech leadership uncertainty may shift competitive dynamics for PfizerBioNTech leadership uncertainty may shift competitive dynamics for PfizerPossible
See all 11 explainers
- JNJ and AbbVie's IMBRUVICA deal may increase pressure on PfizerIncreased competition from JNJ and AbbVie may pressure Pfizer's market share.Possible
- Increased investor focus on Eli Lilly may intensify competition for PfizerIncreased investor focus on Eli Lilly may intensify competition for Pfizer.Possible
- Pfizer may benefit from rising consumer demand for cold and flu medicinesPfizer may see increased sales from early respiratory season demandPossible
- Pfizer may face regulatory risk from counterfeit drug probePfizer faces regulatory risk due to counterfeit drugs using its labelsPossible
- IRA drug price negotiation could reduce Pfizer's net salesIRA's drug price negotiation may reduce Pfizer's net sales revenuePossible
Explainers that pass through Pfizer
Pfizer is a step on the way to someone elseAround Pfizer this week
News at the entities that move Pfizer most-
Brooklyn Shared contextAyan Broomfield uses the Calm app for nervous system calming, lives in Brooklyn, and co-hosts an event with Cadillac.Moves Pfizer
-
FDA StructuralFDA granted 510(k) clearance for combined technologies for Solventum.Moves Pfizer
-
Eli Lilly and Company OperationalMedicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Moves Pfizer
-
Novartis TransactionalSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Pfizer
-
David Denton StructuralWhile revenue declines, Elliott Hill continues as CEO of Nike, and the company announces David Denton as the incoming CFO, who joins from Pfizer.Moves Pfizer
-
Donald Trump StructuralUS embargo on Cuba worsens under Trump pressure, coinciding with a dissident speaking to the European Parliament.Moves Pfizer
Connections
The 40 strongest of 766, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Tina Graves Structural
Tina Graves was a former employee of Pfizer in Canada.
-
Brooklyn Shared context
Pfizer originated in Brooklyn, New York, in 1849.
-
Eli Lilly and Company Operational
Pfizer and Eli Lilly are direct competitors vying for market share in high-growth pharmaceutical sectors, particularly GLP-1 weight loss and oncology.
-
Albert Bourla Structural
Albert Bourla serves as the CEO and Chairman of Pfizer, directing its strategy, operations, and financial outlook.
-
Seagen Structural
Pfizer acquired Seagen in 2023 and integrated it as a subsidiary to bolster its oncology portfolio.
-
Cecile Structural
Cecile has been appointed the Interim Chief Financial Officer of Pfizer.
-
Arvinas (United States) Structural
Pfizer and Arvinas maintain a formal partnership to co-develop and submit vepdegestrant for breast cancer treatment.
-
FDA Structural
FDA formally regulates Pfizer's pharmaceutical products, controlling market entry and compliance through approvals and license enforcement.
Show all 40 connections
-
Novartis Transactional
Novartis acquired Pfizer's Minipress brand and trademarks in India.
-
Moderna Operational
Moderna and Pfizer are direct, high-stakes competitors in the biopharmaceutical market, vying for market share using mRNA technology across various vaccine and gene therapy platforms.
-
Amgen Operational
Pfizer and Amgen are major pharmaceutical competitors actively vying for market share in specialized therapeutic areas, including GLP-1 drugs and biosimilars.
-
Mylan Structural
Mylan was absorbed into the corporate structure stemming from Pfizer's Upjohn division, leading to the formation of Viatris.
-
AstraZeneca Operational
Pfizer and AstraZeneca are active competitors in major biopharma markets, including oncology and functional dyspepsia.
-
Dave Denton Structural
Dave Denton held the formal executive role of Chief Financial Officer at Pfizer during this period.
-
David Denton Structural
David Denton served as the Chief Financial Officer of Pfizer during the observed period.
-
Merck Operational
Pfizer and Merck are major pharmaceutical companies engaged in direct competition across key markets including oncology, candidemia, and glaucoma.
-
Dave Structural
Dave held executive and operational roles, including CFO, within Pfizer.
-
AbbVie Operational
AbbVie and Pfizer are direct competitors in the pharmaceutical industry, vying for market share and investment capital.
-
Hoffmann-La Roche Operational
Pfizer and Hoffmann-La Roche are key competitors in specialized pharmaceutical markets, including Danon Disease and GLP-1 drug development.
-
Donald Trump Structural
Pfizer's operations and pricing are structurally dependent on regulatory mandates and negotiated agreements imposed by the Trump administration.
-
Gensler Transactional
Gensler is contracted to lead the conversion project for Pfizer's building.
-
Johnson & Johnson Operational
Pfizer and Johnson & Johnson are major pharmaceutical competitors operating in shared markets, facing common industry pressures and competing for investment capital.
-
Morgan Stanley Operational
Morgan Stanley actively tracks, rates, and invests in Pfizer stock, co-managing sales and increasing its stake in the company.
-
Arena Pharmaceuticals Structural
Pfizer acquired Arena Pharmaceuticals, establishing a parent-subsidiary relationship.
-
Medicare Structural
Pfizer's market access and revenue are structurally dependent on Medicare's drug negotiation and coverage policies.
-
Eurocontrol Transactional
Pfizer initiated proceedings to freeze Eurocontrol's operational funds to recover outstanding debt.
-
European Commission Structural
Pfizer's market operation in the EU is structurally dependent on the European Commission granting formal marketing authorizations for its products.
-
Wyeth Structural
Pfizer acquired Wyeth in 2009, and Wyeth operates as a dependent subsidiary within the larger corporate structure.
-
Merck KGaA Operational
The companies actively compete in various therapeutic markets, collaborate on specific product approvals, and have engaged in corporate transactions.
-
Tô Lâm Operational
Tô Lâm and Pfizer engage in active cooperation regarding vaccine production and national health priorities.
-
European Medicines Agency Transactional
EMA formally validated Pfizer's vaccine application, initiating the assessment process.
-
Ligand Pharmaceuticals Operational
Ligand Pharmaceuticals and Pfizer maintain ongoing partnerships for drug development and supply.
-
Goldman Sachs International Transactional
Goldman Sachs coordinated and managed the sale of Pfizer's stake in a specific financial transaction.
-
King Pharmaceuticals Structural
King Pharmaceuticals operates as a dependent subsidiary of Pfizer.
-
Viking Therapeutics Operational
The companies are active competitors in the pharmaceutical market, with Pfizer's market shifts creating strategic interest in Viking Therapeutics.
-
Cecile Structural
Cecile holds a senior finance role, including SVP of Finance, within the organizational structure of Pfizer.
-
Michael Law Structural
Michael Law held a functional role on the media team of Pfizer.
-
Control Data Corporation Structural
A is a critical customer of B, establishing a functional dependency on B's product supply and operational stability.
-
RBC Capital Markets Operational
RBC Capital Markets actively advises and co-manages financial activities for Pfizer, including rating upgrades and asset sales.
-
Zoetis Structural
Zoetis originated as a spun-off animal health division of Pfizer in 2013.
History
Events by the month they beganOctober 2026
19 events- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.
- AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.
- Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.
- Novartis and Pfizer provided talent to MindWalk Holdings Corp., while Shuji Sato and Joanne Lim joined the company.
- Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.
- India sought vaccines from Pfizer and Moderna during COVID-19, while Piyush Goyal emphasized the need for self-reliance.
- The article details multiple concurrent political and corporate investigations, including the EC's campaign against Rosatom in Hungary and an EPPO probe into Pfizer's Covid-19 procurement deal.
- Verizon's Frontier deal increased debt, while Kraft Heinz and Pfizer stock traded on Nasdaq.
- Major pharmaceutical companies are competing for investment capital.
- Moderna and Pfizer are developing defenses against Lyme disease, while Tarsus offers a pill for tick threats, amid surveillance discussions.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- Pfizer's performance is being analyzed in comparison to the broader market.
- Both Moderna and Pfizer utilize mRNA technology for gene therapy.
- Prashanth was accused of using Pfizer labels to create fake products.
- Whitney's grandfather purchased shares of Pfizer, and the company subsequently sent money to Florida.
- Cross River State is partnering with Gavi and Pfizer for vaccine delivery and seeking cost reductions from Zipline.
- Getty Images provided the image source for an article involving Pfizer.
September 2026
23 events- Kraft Heinz, Pfizer, and United Parcel Service are all facing financial challenges.
- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.
- Pfizer and other companies are facing administration policy guidance regarding higher drug prices abroad in exchange for revenue sharing with HHS.
- GSK built a joint venture with Pfizer and subsequently distributed a stake in that venture to shareholders.
- IMA Group operates a production site and manufacturing plant in Tonawanda, New York, providing specialized equipment to major customers like Pfizer and Moderna.
- Former Pfizer HQ in Manhattan is discussed alongside Los Angeles as examples of major urban centers facing development challenges and structural issues.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Pfizer, AT&T, and Verizon are companies that trade on the New York Stock Exchange.
- Pfizer and Eli Lilly are being discussed as potential dividend investment targets.
- Pfizer and Seagen are growing their older-adult vaccine market share by expanding the Prevnar 20 vaccination program and rebuilding their commercial model around acquired products.
- Pfizer has refused to cooperate with local investigators regarding an incident in Karnataka.
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.
- The FDA suspended Pfizer's C&F Depot license.
- The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.
- Trump promised drug discounts for low-income Americans and discussed Pfizer deals at a Dallas convention.
- Pfizer CEO Ugur Sahin sold shares of the firm's stock.
- Vaxcyte is targeting the market dominated by Pfizer, and a key individual involved in the story previously worked at Pfizer.
- Pfizer and Boeing were tokenized for use in a crypto launchpad.
- DHS is piloting the 340B program, which affects products manufactured by Pfizer.
- Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.
- Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
- Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.
August 2026
5 events- FDA and Pfizer are seeking regulatory approval for their products.
- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.
- Pfizer conducted initial clinical trials under government review.
- Rand Paul released Fauci's diary ahead of a hearing, while Israel provided Pfizer vaccine data to shape US booster policy.
Show 2 earlier months
June 2026
12 events- Pfizer and AT&T are discussed as blue-chip stocks as of June 30, 2026.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- MarketBeat's screener has identified a list of dividend stocks.
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- Pfizer is jointly marketing the drug Eliquis.
- Study results regarding a drug collaboration between Pfizer and Arvinas narrowed the focus to a specific subset of patients.